Why Most Biotech Startups Don't Make It Past Year 10 (& ...
Scienceinsights·Nov 6, 2025 Why Did Achaogen Fail Despite an FDA-Approved Drug?
Biologyinsights·Jul 22, 2025 What Happened to Achaogen? A Cautionary Tale - Biology Insights
Changes in revenues associated with antimicrobial reimbursement reforms in Germany
Novel insights from financial analysis of the failure to commercialise plazomicin: Implications for the antibiotic investment ecosystem
Achaogen, Inc. - Preference and Fraudulent Transfer Defense Lawyer
Gardnermagazine·Jul 1, 2023 Analysis of Chapter 11 Healthcare Bankruptcies 2019-2022
Achaogen Claims Over Lost Ch. 11 Sales Can Go Forward - Law360
Antibiotic developer Nabriva to wind down
Cipla Calls Achaogen Claims Over Lost Ch. 11 Sales 'Weak' - Law360
Cipla USA furthers AMR stewardship with acquisition of key anti ...
Antibacterial Drug Development: A New Approach Is Needed for the Field to Survive and Thrive
PubMed Central (PMC)·Jul 15, 2020 Antibacterial Drug Development: A New Approach Is Needed ...
Cipla's withdrawal of antibiotic marketing application latest sign of ...
The Washington Post·Jul 9, 2020 Big Drugmakers Launch $1 Billion Fund to Develop New Antibiotics
Bloomberg.com·Jul 9, 2020 Big Drugmakers Launch $1 Billion Fund to Develop New Antibiotics
Bankrupt.com·Jun 15, 2020 200615.mbx - Bankrupt.com
Bloomberg Law·May 28, 2020 Biotech Firm Achaogen Gets Confirmation of Liquidation Plan
